 CAMBRIDGE, Mass., April 11, 2021 GLOBE NEWSWIRE -- Checkmate Pharmaceuticals, Inc. NASDAQ: CMPI Checkmate, a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced the presentation of new translational data from Checkmates Phase 1b trial of vidutolimod CMP-001 in combination with pembrolizumab in patients with advanced anti-PD-1 refractory melanoma. 